Skip to search formSkip to main contentSkip to account menu

Genasense

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

oblimersenoblimersen sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
SummaryBackground: Overexpression of Bcl-2 is associated with worse prognosis for a number of cancer types. The present study was… 
Review
2008
Review
2008
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
Advanced hepatocellular (HCC) is refractory to most standard forms of chemotherapy, however responses to doxorubicin are seen [1… 
Review
2007
Review
2007
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy
Bcl-2 is an oncoprotein that plays a critical role in inhibiting apoptotic cell death in the mitochondria-dependent pathway in… 
2006
2006
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
PURPOSE To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2… 
Highly Cited
2005
Highly Cited
2005
Antisense Bcl‐2 sensitizes prostate cancer cells to radiation
Bcl‐2 is anti‐apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl‐2 has a… 
2004
2004
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term…
7505 Background: Chemotherapy resistance of MM has been linked to Bcl-2, an anti-apoptotic protein over-expressed in > 80% of pts… 
Review
2004
Review
2004
Management of metastatic cutaneous melanoma.
The results of treatment for metastatic melanoma remain disappointing. Single-agent chemotherapy produces response rates ranging… 
Review
2004
Review
2004
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic…
Bcl-2 is an anti-apoptotic protein that has been closely linked to chemotherapy resistance and inferior survival in patients (pts… 
2003
2003
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Bcl-2 is up-regulated by EBV in immortalized lymphoblastoid B cells and is expressed in the majority of EBV-associated… 
2003
2003
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
PURPOSE The near-universal emergence of imatinib resistance in patients with acute forms of Philadelphia chromosome-positive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)